Terbutaline Adult Dosage
For acute bronchospasm in adults, administer terbutaline 0.25 mg subcutaneously every 20 minutes for up to 3 doses, though inhaled beta-agonists are preferred as first-line therapy. For oral maintenance therapy in asthma, the standard dose is 5 mg three times daily (maximum 15 mg/24 hours), though 2.5 mg three times daily may be used if side effects are problematic. 1
Subcutaneous Administration for Acute Bronchospasm
The National Asthma Education and Prevention Program (NAEPP) guidelines clearly specify:
- Dose: 0.25 mg subcutaneously every 20 minutes for 3 doses 1, 2
- Critical caveat: The guidelines explicitly state "no proven advantage of systemic therapy over aerosol" 1
This means subcutaneous terbutaline should be reserved for situations where inhaled therapy cannot be delivered effectively (e.g., severe respiratory distress preventing adequate inhalation, lack of cooperation, or equipment failure). The inhaled route offers faster onset, maximal response, and longer duration with fewer systemic side effects. 3
Oral Dosing for Asthma Maintenance
According to FDA labeling and clinical guidelines:
- Standard adult dose: 5 mg three times daily at approximately 6-hour intervals 4
- Reduced dose option: 2.5 mg three times daily if side effects are particularly disturbing 4
- Maximum daily dose: 15 mg per 24 hours 4
Dosing strategy: Start with 2.5 mg three times daily and titrate upward based on clinical response. Research demonstrates a roughly linear dose-effect relationship up to 7.5 mg three times daily, but increasing from 7.5 mg to 10 mg provides no additional benefit in pulmonary function. 5 If inadequate control persists at 7.5 mg three times daily, adding theophylline 200 mg three times daily is more effective than further increasing terbutaline dose. 5
Nebulized Terbutaline (Not Standard Practice)
While terbutaline can theoretically be nebulized, this is not a standard or recommended route based on the available guidelines. The NAEPP guidelines 1, 2 do not include nebulized terbutaline in their dosing tables for asthma exacerbations—they focus on albuterol, levalbuterol, and other agents for nebulized therapy. Terbutaline appears only in the subcutaneous (injected) beta-agonist section.
Tocolysis: Contraindicated
Terbutaline is explicitly contraindicated for tocolysis (preventing preterm labor). 4, 6 The FDA has issued a boxed warning stating:
- Oral terbutaline should NOT be used for acute or maintenance tocolysis
- It should NOT be used for tocolysis in outpatient or home settings
- Serious adverse reactions including maternal death, cardiac arrhythmias, pulmonary edema, and myocardial ischemia have been reported 4, 6
Important Clinical Considerations
When to avoid subcutaneous terbutaline:
- Patients already receiving adequate inhaled beta-agonist therapy—there is no proven benefit to adding systemic therapy 1
- Patients with cardiovascular disease, given risks of tachycardia, hypokalemia, and potential arrhythmias
- Concurrent use with other sympathomimetics is not recommended 6
Drug interactions requiring caution:
- MAO inhibitors or tricyclic antidepressants (within 2 weeks): extreme caution needed due to potentiated vascular effects 4, 6
- Beta-blockers: may block terbutaline's effects and cause severe bronchospasm 4, 6
- Non-potassium-sparing diuretics: can worsen hypokalemia and ECG changes 4, 6
Monitoring during subcutaneous administration:
- Heart rate and blood pressure (expect transient increases) 7
- Serum potassium (expect decreases, though rarely requiring replacement) 7
- Blood glucose (may cause transient hyperglycemia) 4
Age-specific considerations: